Dr Irene Ghobrial speaks to ecancer about approaches to risk stratification in high-risk myeloma.

Decisions on treating smouldering myeloma focus on whether to start early treatment.

Patients are concerned about progression timelines, highlighting the need for better risk stratification.

With a 10% annual progression rate, current clinical markers help predict outcomes, but dynamic models like PANGEA and genomic analyses provide deeper insights.

Innovations in proteomics and AI aim to enhance risk assessment and treatment strategies for improved patient outcomes.